Mechanism of Action of Spironolactone in Female Pattern Hair Loss
Spironolactone works in FPHL primarily as an androgen receptor (AR) blocker, competitively inhibiting androgen binding at target tissues in the hair follicle, while also reducing adrenal androgen production. 12
Primary Mechanisms
Androgen Receptor Blockade: Spironolactone exerts competitive blockade on androgen receptors in hair follicles, preventing circulating androgens (even at normal levels) from binding to these sensitized receptors and triggering miniaturization of hair follicles. 23
Reduced Androgen Production: The drug inhibits ovarian androgen secretion, leading to sustained reduction in testosterone levels (both total and free testosterone) without affecting adrenal androgens like DHEAS or cortisol. 3
Supporting Evidence
The 2019 Androgen Excess and PCOS Committee guidelines explicitly identify spironolactone as an "AR-blocker" recommended at doses of 100-200 mg/day for FPHL treatment, particularly when severe hair loss or hyperandrogenism is present. 1
Clinical studies demonstrate that spironolactone treatment at 200 mg/day produces:
- Prompt and sustained reduction in ovarian androgen levels
- Inhibition of both ovarian androgen secretion and peripheral androgen action
- Regression of androgen-dependent hair changes within 2 months, with maximal effect at 6 months 3
Even at lower doses (50 mg/day), spironolactone significantly decreases total and free testosterone concentrations while maintaining normal levels of other hormones (LH, FSH, estradiol, progesterone, DHEAS, cortisol). 4
Clinical Context
While spironolactone's FDA-approved mechanism involves aldosterone antagonism at renal tubules 55, its dermatologic efficacy in FPHL relies entirely on its antiandrogenic properties. The drug interferes with androgen-stimulated hair growth patterns, making it effective even in women with normal circulating androgen levels. 67
Important caveat: The antiandrogenic mechanism that makes spironolactone effective for FPHL also creates teratogenic risk through feminization of male fetuses, requiring strict contraception in women of reproductive age. 15
Recent evidence (2025) confirms additive benefit when combined with topical minoxidil, with the mechanism working synergistically—minoxidil promotes anagen phase entry and follicle enlargement while spironolactone blocks the androgen-mediated miniaturization process. 8